Insider · CIK 0001449439
Jeffrey G. Black
Files at XGN (EXAGEN INC.). First filing Nov 19, 2024, latest Sep 2, 2026.
In brief
Jeffrey G. Black files SEC Form 4 as CFO at XGN (EXAGEN INC.). Since Nov 19, 2024, Jeffrey G. Black has reported 1 open-market buy worth $66k and 3 open-market sells worth $355k, the latest filed on Sep 2, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey G. Black has 1, so none is measured yet.
The newest scored trade: sold $149k of XGN on Sep 1, 2026, filed Sep 2, 2026, scored 33 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $154k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XGN: EXAGEN INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | XGNsell EXAGEN INC. | $149k 20,614 shares | -6% | +169% from low-40% from high | |
| 30Weak | EXAGEN INC. | $5,718 1,584 shares | -1% | +29% from low-69% from high | |
| 34Weak | XGNsell EXAGEN INC. | $200k 20,466 shares | -7% | +295% from low-5% from high | |
| 41Moderate | EXAGEN INC. | $66k 22,298 shares | +9% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 12, 2024 | LAB STANDARD BIOTOOLS INC. | 57,971 0.02% of outstanding | $123k | Nov 12, 2024 | $109k |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -20,614 | $7.22 | $149k | 323,339 | 41 d ago |
| Sep 1, 2026 | XGN EXAGEN INC. | AGrant or award Common Stock | +1,571 | $3.02 | $4,740 | 324,910 | 41 d ago |
| Mar 12, 2026 | XGN EXAGEN INC. | AGrant or award Common Stock | +75,000 | $3.16 | $237k | 342,442 | Mar 16, 2026 |
| Feb 27, 2026 | XGN EXAGEN INC. | AGrant or award Common Stock | +1,511 | $3.08 | $4,649 | 343,953 | Mar 16, 2026 |
| Mar 12, 2026 | XGN EXAGEN INC. | AGrant or award Stock Option(right to buy)derivative | +50,000 | $3.16 | $158k | 60,000 | Mar 16, 2026 |
| Feb 24, 2026 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -1,584 | $3.61 | $5,718 | 267,442 | Feb 25, 2026 |
| Sep 2, 2025 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -20,466 | $9.79 | $200k | 269,026 | Sep 4, 2025 |
| Feb 21, 2025 | XGN EXAGEN INC. | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 289,492 | Feb 25, 2025 |
| Feb 21, 2025 | XGN EXAGEN INC. | AGrant or award Stock Option(right to buy)derivative | +10,000 | $3.58 | $36k | 10,000 | Feb 25, 2025 |
| Nov 15, 2024 | XGN EXAGEN INC. | POpen-market purchase Common Stock | +22,298 | $2.98 | $66k | 274,492 | Nov 19, 2024 |
Questions about Jeffrey G. Black
Answered from the filings on this page, as of the latest one.
Is Jeffrey G. Black buying or selling?
In the last 12 months Jeffrey G. Black reported 0 open-market buys worth $0 and 2 open-market sells worth $154k on SEC Form 4; the latest was sold $149k of XGN on Sep 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey G. Black's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey G. Black has 1.
Where does Jeffrey G. Black file Form 4?
Jeffrey G. Black has filed Form 4 at XGN (EXAGEN INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.